期刊文献+

骨碱性磷酸酶、N-端骨钙素在重组人甲状旁腺素(1-34)治疗原发性骨质疏松症疗效观察中的应用 被引量:17

Bone alkaline phosphatase and N-MID osteocalcin in monitoring of osteoporosis treatment with recombinant human parathyroid hormone1-34
下载PDF
导出
摘要 目的:探讨血清骨转换指标骨碱性磷酸酶(BALP)和N-端骨钙素(N-MID)水平监测在重组人甲状旁腺素(1-34)治疗原发性骨质疏松症疗效观察中的作用.方法:采用双能X-线骨密度仪测定患者治疗前、治疗后6个月及12月时腰椎L2~L4和股骨颈骨密度;同时采用化学发光仪及电化学发光仪检测血清BALP及N-MID水平.结果:与用药前相比,患者在用药6个月后股骨颈骨密度无变化,腰椎L2~L4骨密度均值由治疗前0.753g/cm^2上升到0.781 g/cm^2,上升了3.7%(P<0.05);而血清N-MID水平由15.46 ng/ml上升到27.07 ng/ml,BALP水平均值由14.05 μg/ml上升到24.31 μg/m,分别上升了75.1%和73.0%(均P<0.01).用药12个月后,患者股骨颈骨密度与用药前比较仍无明显变化(P>0.05),腰椎L2~L4骨密度由0.753 g/cm^2上升到0.807 g/cm^2,上升了7.2%(P<0.01);而血清N-MID和BALP水平由用药前15.46 ng/ml、14.05 μg/ml上升到49.38 ng/ml、33.99 μg/ml,与治疗前相比分别上升了219.4%和141.9%(均P<0.01).结论:在促进骨合成的骨质疏松治疗中,血清N-MID及BALP水平较骨密度测量更敏感.因此,骨密度测量联合血液骨转化标志指标检测,可以对骨质疏松疗效进行有效监测. Objective:To evaluate the application of bone turnover markers bone alkaline phosphatase (BALP) and N-MID osteocalcin (N-MID) in monitoring of osteoporosis treatment with recombined parathyroid hormone 1-34 (rhPTH1-34).Methods:The bone mineral density (BMD) of the lumbar spine L2-L4 and the proximal femur were examined by dual energy X-ray absorptiometry (DXA) before and 6 and 12 months after rhPTH 1-34 treatment.Meanwhile,serum levels of BALP and N-MID were detected by electro-chemiluminescence assay.Results:Six months after rhPTH 1-34 treatment,the BMD of proximal femur remained unchanged,and the BMD of the lumbar L2-L4 spine increased from 0.753 g/cm^2 to 0.781 g/cm^2 (P 〈0.05) ; while serum levels of N-MID increased from 15.46 ng/ml to 27.07 ng/ml(P 〈 0.01),BALP from 14.05 μg/ml to 24.31 μg/ml (P 〈 0.01).Twelve months after drug administration,no significant changes were observed in BMD of proximal femur,and the BMD of the lumbar spine L2-L4 increased from 0.753 g/cm^2 to 0.807 g/cm^2 (P 〈 0.01) while serum levels of N-MID and BALP increased from 15.46 ng/ml and 14.05μg/ml to 49.38 ng/ml and 33.99 μg/ml,respectively (both P 〈 0.01).Conclusion:Serum levels of BALP and N-MID are more sensitive than BMD.Combination of two methods may provide better indicators for monitoring of osteoporosis treatment.
出处 《浙江大学学报(医学版)》 CAS CSCD 北大核心 2013年第5期578-582,共5页 Journal of Zhejiang University(Medical Sciences)
关键词 骨质疏松 碱性磷酸酶 骨钙素 甲状旁腺素 骨密度 治疗结果 病例对照研究 Osteoporosis Alkaline phosphatase Osteocalcin Parathyroid hormone Bone density Treatment outcome Case-control studies
  • 相关文献

参考文献17

  • 1NORTH AMERICAN MENOPAUSE SOCIETY Management of postmenopausal osteoporosis, posit ion statement of the North American Menopause Society [ J ]- Menopause, 2002,9 (2) :84-101. 被引量:1
  • 2HODGSON S F, WATTS N B, BILEZIKIAN J P, et al. American Association of Clinical Endocrinologist s medical guidelines for clinical practice for the prevent ion and treatment of postmenopausal osteoporosis:2001 edition,with selected updates for 2003 [ J]. Endoer Praet,2003,9(6) :544-564. 被引量:1
  • 3EL MAGHRAOUI A,DO SANTOS ZOUNON A A, JROUNDI I, et al. Reproducibility of bone mineral density measurements using dual Xray absorpt iometry in daily clinical pract ice [ J ]. Osteoporos Int,2005,16(12) : 1742-1748. 被引量:1
  • 4CHINESE MEDICAL ASSOCIATION Clinical Guidelines: Volumes of osteporosid and Mineral Disease [ M ]. Beijing: People' s Medical Publishing House,2006:2-4. 被引量:1
  • 5KNEISSEL M, BOYDE A, GASSER J A, et al. Bone tissue and its mineralization in aged estrogen- depleted rats after long-time intermittent treatment with parathyroid hormone(PTH) analog SDZPTS893 or human PTH (1-34) [ J ]. Bone, 2001,28 (3) : 237-250. 被引量:1
  • 6LIDA-KLEIN A, LU SS, KAPADIA R, et al. Short- term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice [ J ]. J Endocrinol,2005,186 (3) : 549-557. 被引量:1
  • 7THOMAS T. Intermittent parathyroid hormonetherapy to increase bone formation [J]. Joint Bone Spine,2006,73 (3) :262-269. 被引量:1
  • 8ZHANG L,YANG M, LIU D, et al. The rhPTH ( 1- 34 ), but not elcatonin, increases bone anabolic efficacy in postmenopausal women with osteoporosis [J]. Exp Clin Endocrinol Diabetes, 2012, 120 (6) :361-366. 被引量:1
  • 9LIULL,ZHANGZY,CHENL(刘莉莉,张忠英,陈亮),etaJ.EvaluationofbonetUlTIOVeFbydetecting serum beta-collage degradation products and osteocalcin concentration [ J ]. Journal of Clinical Rehabilitative Tissue Engineering Reasearch , 2007,11 (2) :268-270. 被引量:1
  • 10GUNDBERG C M. Biochemical markers of bone formation [ J ]. Clin Lab Meal, 2000,20 ( 3 ) :489- 501. 被引量:1

二级参考文献1

共引文献11

同被引文献207

引证文献17

二级引证文献152

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部